Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer

Carbone, Federico; Grossi, Francesco; Bonaventura, Aldo; Vecchiè, Alessandra; Minetti, Silvia; Bardi, Nicholas; Elia, Edoardo; Ansaldo, Anna Maria; Ferrara, Daniele; Rijavec, Erika; Bello, Maria Giovanna Dal; Biello, Federica; Rossi, Giovanni; Tagliamento, Marco; Alama, Angela; Coco, Simona; Spallarossa, Paolo; Dallegri, Franco; Genova, Carlo

doi:10.1007/s10585-019-09984-z

Cited by 16 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, except for PD-L1 tissue expression (>50%) that is used to select advanced NSCLC patients to receive pembrolizumab in the first line setting, no reliable prognostic or predictive marker is presently acknowledged for other ICIs. In this context, in preclinical studies, we found that circulating markers may have significant results [29,95,96]. Moreover, the correlation between PD-L1 expression on CTCs and prognosis of advanced patient cohorts treated with immunotherapy has been explored.…”

Section: Discussionmentioning

confidence: 99%

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges

Rijavec

Coco

Genova

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged as novel approaches for more tailored treatments, repeated assessments of the tumor biology have become pivotal to drive clinical decisions. Currently, tumor tissue biopsy is the gold standard to investigate potentially actionable biomarkers, but this procedure is invasive and may prove inadequate to represent the whole malignancy. In this regard, liquid biopsy represents a minimally invasive and more comprehensive option for early detection and investigation of this tumor. Today, cell-free DNA is the only approved circulating marker to select patients for a targeted therapy. Conversely, the other tumor-derived markers (i.e., circulating tumor cells, miRNAs, exosomes, and tumor educated platelets) are still at a pre-clinical phase, although they show promising results for their application in screening programs or as prognostic/predictive biomarkers. The main challenges for their clinical translation are the lack of reliable cutoffs and, especially for miRNAs, the great variability among the studies. Moreover, no established tool has been approved for circulating tumor cells and exosome isolation. Finally, large prospective clinical trials are mandatory to provide evidence of their clinical utility.

show abstract

Section: Discussionmentioning

confidence: 99%

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges

Rijavec

Coco

Genova

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Immune resistance mediated by hypoxia is supported by preclinical experiments involving notch-hedgehog signalling and CSCs [ 271 ] Interestingly, therapeutic oxygenation may reverse this immune resistance [ 272 , 273 ]. However, only a few studies have investigated immune responses considering tumour hypoxic characterisation [ 274 , 275 , 276 ].…”

Section: Prognostic Implications Of Hypoxia In Lung Cancermentioning

confidence: 99%

Hypoxia in Lung Cancer Management: A Translational Approach

Ancel

Perotin

Dewolf

et al. 2021

Cancers

View full text Add to dashboard Cite

Lung cancer represents the first cause of death by cancer worldwide and remains a challenging public health issue. Hypoxia, as a relevant biomarker, has raised high expectations for clinical practice. Here, we review clinical and pathological features related to hypoxic lung tumours. Secondly, we expound on the main current techniques to evaluate hypoxic status in NSCLC focusing on positive emission tomography. We present existing alternative experimental approaches such as the examination of circulating markers and highlight the interest in non-invasive markers. Finally, we evaluate the relevance of investigating hypoxia in lung cancer management as a companion biomarker at various lung cancer stages. Hypoxia could support the identification of patients with higher risks of NSCLC. Moreover, the presence of hypoxia in treated tumours could help clinicians predict a worse prognosis for patients with resected NSCLC and may help identify patients who would benefit potentially from adjuvant therapies. Globally, the large quantity of translational data incites experimental and clinical studies to implement the characterisation of hypoxia in clinical NSCLC management.

show abstract

“…CD4 + T cells, NLR and myeloid‐derived suppressor cells have been proposed as potential blood‐derived biomarkers 14,15 . Previous results of our group outlined the potential prognostic role of some inflammation‐related biomarkers, such as osteopontin, resistin and pro‐convertase subtilisin‐kexin 9 (PCSK9) 6,16,17 . Besides, interleukin 6 and cell‐free DNA have been proposed as prognostic serum biomarkers 18 .…”

Section: Discussionmentioning

confidence: 96%

Serum levels of VCAM‐1 are associated with survival in patients treated with nivolumab for NSCLC

Carbone

Ministrini

Bonaventura

et al. 2021

Eur J Clin Investigation

Self Cite

View full text Add to dashboard Cite

Background High circulating levels of cellular adhesion molecules (CAMs) in non‐small cell lung cancer (NSCLC) have been supposed to act as a negative prognostic factor. Here, we explored the predictive role of pre‐treatment levels of CAMs in previously treated patients receiving nivolumab for NSCLC. Materials and methods Seventy one patients with advanced NSCLC, treated with nivolumab at the dose of 3 mg/kg every 14 days, were enrolled. Maximum follow‐up time was 3 years. Serum levels of Vascular Cell Adhesion Molecule‐1 (VCAM‐1) and Intracellular Adhesion Molecule‐1 (ICAM‐1) were measured at baseline and before each nivolumab administration. Endpoints of the study were a composite outcome of survival ≥2 years or absence of disease progression at the end of the follow‐up, and the overall survival. Results Composite outcome and overall survival were positively associated with VCAM‐1 baseline levels and with the reduction of VCAM‐1 during the treatment. After adjustment for potential confounders, the change in VCAM‐1 serum levels during the treatment was an independent predictor of overall survival. Conclusions High baseline serum levels of VCAM‐1 are associated with a longer survival in patients treated with nivolumab as second line treatment for NSCLC. Surviving patients experience also a significant reduction in CAMs expression during the treatment. Hence, CAMs might be promising prognostic factors in patients with NSCLC underoing immunotherapy.

show abstract

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer

Cited by 16 publications

References 31 publications

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges

Hypoxia in Lung Cancer Management: A Translational Approach

Serum levels of VCAM‐1 are associated with survival in patients treated with nivolumab for NSCLC

Contact Info

Product

Resources

About